Elizabeth R. Plimack, MD; Fox Chase Cancer Center 5Live #ASCO20
2:47
Key insights on Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
Renal Cell Carcinoma
Elizabeth R. Plimack, MD; Fox Chase Cancer Center 5Live #ASCO20
Key insights on Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
